Shah S U, Socha M, Sejil C, Gibaud S
Faculté de pharmacie, université de Lorraine, EA 3452/CITHEFOR-5, rue Albert-Lebrun, 54000 Nancy, France; Departement of Pharmaceutics, Faculty of Pharmacy, Gomal University, Dera Ismail Khan (KPK), Pakistan.
Faculté de pharmacie, université de Lorraine, EA 3452/CITHEFOR-5, rue Albert-Lebrun, 54000 Nancy, France.
Ann Pharm Fr. 2017 Mar;75(2):95-104. doi: 10.1016/j.pharma.2016.09.001. Epub 2016 Oct 19.
In recent years, S-nitrosoglutathione has been proposed for the treatment of Crohn's disease to prevent mucosal barrier failure. In this paper, we report the formulation of spray dried microparticles of glutathione and S-nitrosoglutathione based on Eudragit FS 30D polymer (i.e. colon-specific delivery system).
The influence of several spray-drying parameters (inlet temperature 80-150°C, solvent flow 5-10mL/min) was studied. The parameters that yielded the best formulations (inlet temperature 120°C, outlet temperature 47°C, solvent flow 5mL/min and air flow 100%) were selected for further studies.
Scanning electron microscopy revealed that the resulting microparticles were spherical in shape. The powder X-ray diffraction patterns of pure GSH and GSNO showed sharp peaks that were not present in the microparticles, confirming a molecular dispersion of the drugs by the polymer. The stability of the drugs in the microparticles was confirmed by Fourier transform infrared spectroscopy. Release studies in phosphate buffer solutions showed fast release at basic pH 7.4, sustained release at pH 6.8, but practically no release at the acidic pHs of 1.2, 3 and 6 for the pH-sensitive microparticles. The microparticles prevented the release of drugs at acidic pH while demonstrating fast release at basic pH 7.4; this suggests the suitability of these microparticles to be evaluated for specific colon targeting.
Using Eudragit FS 30D as a gastro-resistant rate-controlling polymer, S-nitrosoglutathion could be targeted to the colon for further studies in the treatment of inflammatory bowel diseases including Crohn's disease.
近年来,已提出用S-亚硝基谷胱甘肽治疗克罗恩病以防止黏膜屏障破坏。在本文中,我们报告了基于Eudragit FS 30D聚合物(即结肠特异性递送系统)的谷胱甘肽和S-亚硝基谷胱甘肽喷雾干燥微粒的制剂。
研究了几个喷雾干燥参数(进口温度80 - 150°C,溶剂流速5 - 10mL/min)的影响。选择产生最佳制剂的参数(进口温度120°C,出口温度47°C,溶剂流速5mL/min和气流100%)进行进一步研究。
扫描电子显微镜显示所得微粒呈球形。纯谷胱甘肽(GSH)和S-亚硝基谷胱甘肽(GSNO)的粉末X射线衍射图谱显示出尖锐峰,而这些峰在微粒中不存在,证实了药物被聚合物分子分散。通过傅里叶变换红外光谱证实了药物在微粒中的稳定性。在磷酸盐缓冲溶液中的释放研究表明,对于pH敏感微粒,在碱性pH 7.4时快速释放,在pH 6.8时持续释放,但在酸性pH 1.2、3和6时几乎不释放。微粒在酸性pH下阻止药物释放,而在碱性pH 7.4时显示快速释放;这表明这些微粒适合用于特定结肠靶向的评估。
使用Eudragit FS 30D作为胃抗性控释聚合物,S-亚硝基谷胱甘肽可靶向结肠,用于包括克罗恩病在内的炎症性肠病治疗的进一步研究。